GI Infections and Inflammation: Symptoms, Diagnostics, and Modern Treatment Approaches

Common Gastrointestinal Issues: From Bacteria to Inflammation

The gastrointestinal (GI) tract is a complex system susceptible to numerous factors, ranging from diet to microorganisms. Various infections and inflammatory processes can cause a wide range of symptoms, significantly reducing quality of life. Understanding the causes and mechanisms behind these conditions is key to effective diagnosis and treatment.

Helicobacter pylori: The Hidden Culprit Behind Many GI Issues

Since its discovery in 1982, the bacterium Helicobacter pylori (H. pylori) has been recognized as one of the primary causes of chronic stomach diseases, affecting more than half of the world's population [5]. This bacterium causes chronic gastritis, which can progress to peptic ulcer disease of the stomach and duodenum, and significantly increases the risk of gastric cancer [5].

Symptoms of H. pylori infection are often non-specific and include [5]:

• Discomfort and pain in the upper abdomen
• Abdominal bloating
• Loss of appetite
• Nausea
• Heartburn

These symptoms occur due to the body's inflammatory response and the action of bacterial toxins, such as VacA and CagA, which damage the gastric mucosa [5]. Prolonged inflammation disrupts the protective barrier of the stomach, making it vulnerable to stomach acid and ulcer formation [5].

Treatment for H. pylori traditionally involves triple therapy consisting of a proton pump inhibitor (e.g., rabeprazole) and two antibiotics (amoxicillin and clarithromycin) for a course of 10 or 14 days [5]. However, treatment efficacy may decrease due to side effects and the development of antibiotic resistance [7].

The Role of Microbiota and Probiotics in Treating GI Disorders

Antibiotic therapy, necessary for H. pylori eradication, frequently leads to intestinal dysbiosis, causing side effects such as vomiting, diarrhea, and general fatigue [7]. In this context, probiotics play an important role in supporting GI health and mitigating adverse reactions.

Recent studies have shown that multi-strain probiotic supplements can significantly alleviate gastrointestinal symptoms associated with bismuth quadruple therapy (BQT) for H. pylori without reducing eradication efficacy [1]. A four-week course of probiotics reduced reflux, dyspepsia, and diarrhea, improving patient comfort [1]. Traditional Chinese medicine may also exert a similar regulatory effect on the gut microbiota [1].

Certain probiotic strains, such as Lactococcus garvieae LG3092, are capable of modulating the gastric microbiota and reducing inflammation caused by H. pylori through the secretion of specific substances targeting pro-inflammatory bacteria [7]. This opens up new prospects for reducing antibiotic side effects and increasing treatment efficacy.

In addition to H. pylori, microbiota imbalance is linked to other conditions such as irritable bowel syndrome (IBS) [6] and even migraine in children with concurrent GI symptoms [8]. Research demonstrates the therapeutic potential of certain strains, such as the Lachnospiraceae family in IBS [6] and Bifidobacterium longum in pediatric migraine, highlighting the gut-brain axis connection [8].

Rare Forms of Gastritis: Diagnostic Challenges

Beyond common infections, there are rarer but serious inflammatory gastric diseases. These include:

• Collagenous gastritis (CG): This is an extremely rare chronic inflammatory gastric disease characterized by thickening of the subepithelial collagen layer and infiltration by inflammatory cells [2, 4]. CG symptoms are non-specific, leading to a high rate of misdiagnosis [2]. It can manifest as postprandial epigastric discomfort, anorexia, dizziness, fatigue, and severe iron-deficiency anemia, particularly in young adults [2]. Endoscopy may reveal diffuse erythema, erosions, and characteristic nodular-depressed changes [2, 4]. The diagnosis is confirmed by histopathological examination [2, 4].
• Emphysematous gastritis (EG): This is a rare, life-threatening condition characterized by the presence of gas within the stomach wall caused by gas-forming bacteria, often accompanied by hepatic portal venous gas [3]. EG can develop against the background of a weakened immune system, such as in cancer patients undergoing chemotherapy [3]. Symptoms may include sepsis and altered mental status [3]. Treatment generally involves broad-spectrum antibiotics [3].

These cases emphasize the importance of thorough diagnostics and an individualized approach to treatment, especially in the presence of atypical symptoms or comorbidities.

Conclusion: A Comprehensive Approach to GI Health

Gastrointestinal health depends on numerous factors, including microbiota balance and the absence of pathogenic microorganisms. H. pylori infection is one of the most common causes of gastritis, ulcers, and an increased risk of stomach cancer. Modern treatment approaches include not only antibiotics and proton pump inhibitors, but also probiotics, which help minimize side effects and maintain a healthy intestinal microflora. At the same time, it is important to keep in mind rare but serious conditions such as collagenous and emphysematous gastritis, which require specialized diagnostics and treatment. If you experience any concerning GI symptoms, consult a healthcare professional for accurate diagnosis and an appropriate treatment plan.

References

• [1] Liu, Y., Zhang, Y., Li, S., Wang, Y., Zhang, R., Li, Y., ... & Li, Y. (2026). Traditional Chinese medicine alleviate gastrointestinal symptoms during bismuth quadruple therapy for Helicobacter pylori infection: A complementary perspective. World Journal of Gastroenterology, 32(1). https://pubmed.ncbi.nlm.nih.gov/41810439/
• [2] Li, J., Li, Y., & Chen, G. (2026). Collagenous gastritis: a rare case in young adult with iron deficiency anemia. Revista Española de Enfermedades Digestivas, 118(1). https://pubmed.ncbi.nlm.nih.gov/42089487/
• [3] Ahmed, A., & Ahmad, A. (2025). Emphysematous Gastritis in the Setting of Stage Four Colon Cancer After Radiation Therapy and Ongoing Chemotherapy: A Case Report. Cureus, 17(1). https://pubmed.ncbi.nlm.nih.gov/41040759/
• [4] Li, Y., Li, J., & Chen, G. (2026). Case Report: Scar-Like Alterations of the Gastric Mucosa Observed Under Endoscopy in Collagenous Gastritis. Clinical Case Reports, 14(1). https://pubmed.ncbi.nlm.nih.gov/41970289/
• [5] Al-Saffar, H. A., & Al-Saffar, A. H. (2025). Innovative approaches in HELICOBACTER pylori therapy: Clinical trials and advancements in Gastro-Retentive drug delivery systems. Arab Journal of Gastroenterology: The Official Publication of the Pan-Arab Association of Gastroenterology, 26(1). https://pubmed.ncbi.nlm.nih.gov/41206255/
• [6] Li, Y., Li, S., Wang, Y., Zhang, R., Li, Y., & Li, Y. (2026). Therapeutic potential of Lachnospiraceae strains in irritable bowel syndrome via differential gut-brain pathways. Microbiome Research Reports, 1(1). https://pubmed.ncbi.nlm.nih.gov/42272860/
• [7] Li, Y., Zhang, Y., Li, S., Wang, Y., Zhang, R., Li, Y., ... & Li, Y. (2025). Garvicin Q-producing Lactococcus garvieae LG3092: its role in mitigating dysbiosis and H. pylori-associated gastritis. NPJ Biofilms and Microbiomes, 11(1). https://pubmed.ncbi.nlm.nih.gov/41315330/
• [8] Li, Y., Zhang, Y., Li, S., Wang, Y., Zhang, R., Li, Y., ... & Li, Y. (2026). Targeting the microbiome in pediatric migraine: gastrointestinal manifestations and the therapeutic role of Bifidobacterium longum. Gut Microbes, 17(1). https://pubmed.ncbi.nlm.nih.gov/41454664/

Disclaimer: The information presented in this article is for reference purposes only and is not intended for self-diagnosis or self-treatment. Always consult a qualified medical professional for an accurate diagnosis and an individualized treatment plan.